Abstract
OBJECTIVES
Up-regulation of tenascin C (TNC), a matricellular protein, produced mainly by vascular smooth muscle cells (VSMC), is associated with the progression and dilation of abdominal aortic aneurysms (AAA). The aims of this study were (i) to evaluate whether serum levels of TNC in patients with AAA patients correlate with aortic diameter and (ii) to clarify the role of TNC in formation and progression of AAA in a murine model.
METHODS
In 15 patients with AAA serum levels of TNC were measured and correlated with aortic diameters. Moreover, in a murine calcium chloride AAA model, the impact of TNC deficiency on AAA diameter was evaluated. Finally, human VSMC were incubated with TNC to clarify its regulating potential.
RESULTS
In the clinical cohort, there was a trend of correlation between serum TNC levels and AAA diameter (P = 0.055). TNC knock out mice with AAA showed significantly lower diameter ratios compared to the wild-type group (WT) 3 weeks (P < 0.05) and 10 weeks (P < 0.05) after AAA induction. Immunohistochemistry revealed increased TNC expression in aortic tissue from WT with AAA as compared sham-operated mice. Furthermore, WT with AAA showed a more disrupted Elastin structure than TNC knock out mice 10 weeks after AAA induction. In human aortic VSMC, TNC incubation induced expression of remodelling associated proteins.
CONCLUSIONS
TNC might play a causative role in the formation, dilation and progression of AAA. Our results indicate that TNC might be a biomarker as well as a potential therapeutic target in the treatment of AAA.
Keywords: Abdominal aortic aneurysm, Tenascin C, Serum marker, Extracellular matrix
Abdominal aortic aneurysms (AAA) are defined as dilations of the abdominal aorta with more than 30 mm diameter in men and are a risk factor for rupture [1].
INTRODUCTION
Abdominal aortic aneurysms (AAA) are defined as dilations of the abdominal aorta with more than 30 mm diameter in men and are a risk factor for rupture [1]. Therefore, in asymptomatic AAA patients with no additional risk factors, an abdominal aorta diameter of more than 50–55 mm is recommended as indication for surgical or endovascular repair [1]. While management of risk factors e.g. arterial hypertension and smoking is standard of care, no causal medical treatment has yet proven to be an advantage in randomized placebo-controlled trials [1, 2].
Mechanistically, chronic inflammation is associated with the development of AAA leading to vascular smooth muscle cells (VSMC) proliferation and apoptosis as well as extracellular matrix dysregulation [2]. More recently, experimental studies demonstrated that the up-regulation of tenascin C (TNC), a matricellular glycoprotein, correlates with AAA progression [3, 4]. Moreover, our group showed that an elevated TNC expression in patients with acute Type A dissection of the ascending aorta, probably acts as a factor of destabilization [5]. Similarly, previous preclinical and clinical studies provided further evidence that pathophysiologic adverse remodelling has been improved in TNC deficient mice with pressure overload induced left ventricular hypertrophy or myocardial infarction [6, 7].
The present study aimed (i) to evaluate whether TNC serum levels correlate with aortic diameters in patients with AAA and (ii) to clarify the causative role of TNC on AAA formation in a murine TNC knockout model as well as human aortic VSMC culture.
MATERIALS AND METHODS
Patient cohort of abdominal aortic aneurysms
The study was approved by the institutional ethics committee at the Medical University of Vienna (1729/2014) and performed according to the Declaration of Helsinki. Due to the confounding effects on TNC expression, exclusion criteria were: active infections and carcinoma diagnosed during the preceding 5 years [8–10]. TNC levels in serum were measured by enzyme-linked immunosorbent assay (ab213831, Abcam, Cambridge, UK) according to the manufacturer’s recommendations. Syngo.via—CT vascular software (V. 5.1, Siemens Healthcare GmbH, Erlangen, Germany) was used for diameter measurements as well as three-dimensional reconstructions. The maximum aortic diameter in computed tomography angiography was measured perpendicularly to the aortic axis after multiplanar reformation.
Murine abdominal aortic aneurysm model and organ preparation
The experimental protocol was approved by the Ethics Committee for Laboratory Animal Experiments at the Medical University of Vienna and the Austrian Ministry of Science Research and Economy (BMWFW-66.009/0278-II/3b/2012) as well as conforms with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996).
In male, 9-week-old A/J wild type (WT) and A/J TNC knock out mice [A/J-TgH(Tnc), RBRC00007, RIKEN BioResource Center, Tsukuba, Ibaraki, Japan] AAA were induced by periaortic calcium chloride (CaCl2) application, as described by Chiou et al. [11–14]. Shortly, after subcutaneous administration of buprenorphine (0.1 mg/kg body weight) and sedation with 4% isoflurane, mice were intubated. Under continuous ventilation with 2% isoflurane, median laparotomy was performed. After preparation of the infrarenal aorta, its diameter was measured with the operating microscope, as described by Chiou et al. [14]. Subsequently, a 5 × 10 mm piece of cotton gauze soaked with 0.5 M CaCl2 (Amresco E506-100ML CaCl2 1 M Sterile Solution, VWR International GmbH, Darmstadt, Germany; diluted 1:1 with 0.9% sodium chloride) was applied on the surface of the aorta for 15 min. The gauze was removed and the laparotomy was closed. After recovery of spontaneous breathing, mice were extubated. Piritramide (30 mg piritramide diluted in 10 ml Glucose 10% + 250 ml Water) in the drinking water was used for postoperative analgesia. Sham groups were treated identically, but sodium chloride (0.9%) was used instead of CaCl2 application.
Aortic diameter measurement and tissue harvesting were performed 3 and 10 weeks after AAA induction under deep sedoanalgesia with intraperitoneal administration of ketamine (100 mg/kg body weight) and xylazine (5 mg/kg body weight). Again, the infrarenal aorta was prepared and the aortic diameter was measured with the operating microscope (Supplementary Material, Fig. S1). The primary endpoint was the ratio between the aortic diameter at AAA induction and at organ harvesting [14].
Tenascin C immunohistochemistry
Formalin-fixed, paraffin-embedded samples harvested 3 weeks after AAA induction were sectioned at 2 µm thickness and stained according to instructions provided for the ABC staining kit (Vectastain Elite, Vector laboratories). Importantly, antigen retrieval was performed by immersing rehydrated sections in Tris-HCL buffer, pH 7.4, containing protease (Type XIV from Streptomyces griseus) at a concentration of 1.9 mg/ml at 37°C for 13 min. Incubation with primary antibody against TNC (ab19011, Abcam, 1:1000 dilution) was performed overnight at 4°C. Sections were imaged using an AxioImager.M2 microscope equipped with an AxioCam 512 colour camera (both Zeiss) at 10× magnification, and staining intensity was semi-quantitatively scored by an observer blinded to experimental conditions.
Elastica van Gieson staining and analysis
Formalin-fixed, paraffin-embedded samples harvested 10 weeks after AAA induction were sectioned at 4 µm thickness and were stained according to the manufacturer’s (Morphisto GmbH, Frankfurt am Main, Germany) recommendations. The degree of elastin degradation was semi-quantitatively scored by 2 observers blinded to experimental conditions as previously described [15]. An average was calculated for each section.
Human aortic vascular smooth muscle cell culture
Human aortic VSMC were cultured using M199 complete media supplemented with 20% foetal bovine serum and 1% Penicillin and Streptomycin. Cells were treated for 24 h under following conditions: (i) Control, (ii) 0.1 µM angiotensin II (Ang II) (Merck, Darmstadt, Germany), (iii) 10 µg/ml TNC (Merck, Darmstadt, Germany) and (iv) 10 µg/ml TNC in addition to 50 nM TAK-242 (Merck, Darmstadt, Germany). After the treatment, total RNA was isolated using RNeasy Mini kit (Qiagen, Hilden, Germany) and expression of target genes (related to AAA formation and linked to TNC [16], Supplementary Material, Table S1) were assessed by reverse transcription and quantitative polymerase chain reaction.
Reverse transcription and quantitative polymerase chain reaction
Total RNA was transcribed into cDNA using QuantiTect reverse transcription kit (Qiagen, Hilden, Germany). Samples were measured in duplicates to a final reaction volume of 20 μl per well. The initial denaturation step of 5 min at 95°C was followed by 40 cycles of 15 s 95°C, 30 s 50°C and 30 s 72°C, using ROTOR-Gene Q (Qiagen, Hilden, Germany) and Rotor-Gene Q series software for computed tomography value analysis. GAPDH was used as housekeeping gene to normalize yielded Ct-values. Relative gene expression was calculated using 2−ΔΔCt method.
Data acquisition and statistical analysis
All data are shown as mean ± standard deviation. One-way ANOVA with Tukey-HSD post hoc analysis as well as unpaired t-tests was used to compare means in different groups. Pearson correlation coefficient was calculated. P-values of <0.05 were considered significant. Levels of significance are shown as follows: *P < 0.05, **P < 0.01 and ***P < 0.001.
Data analysis and visualization were performed in R for Mac (R 3.0.2, The R foundation for Statistical Computing, Vienna, Austria). The following R packages were used: Hmisc, plotrix and splines.
RESULTS
Serum tenascin C levels in patients with abdominal aortic aneurysms
A cohort of 18 patients with AAA was screened, of which 15 patients were included. Patient characteristics are shown in Table 1. The patients showed an average maximal aortic diameter of 60.4 ± 11.8 mm and average TNC levels of 8744 ± 5836 pg/ml. The serum level of TNC showed a trend of positive correlation with the maximal aortic dimension (Fig. 1; r = 0.505, P = 0.055). Representative computed tomography images and three-dimensional reconstructions with abdominal aorta dimension as well as serum TNC levels of 2 patients are shown in Fig. 2.
Table 1:
Patient characteristics
| Age (years) | 67.0 ± 8.0 |
| Gender (male) | 15 (100%) |
| Body mass index | 26.8 ± 2.8 |
| Serum tenascin C (pg/ml) | 8744 ± 5836 |
| Maximum AAA diameter [mm] | 60.4 ± 11.8 |
| Aneurysm morphology | |
| Fusiform | 12 (80%) |
| Saccular | 3 (20%) |
| Positive family history | 2 (13.3%) |
| Arterial hypertension | 13 (86.7%) |
| Hyperlipidaemia | 11 (73.3%) |
| Diabetes mellitus | 2 (13.3%) |
| Peripheral artery disease | 3 (20%) |
| Coronary artery disease | 3 (20%) |
| Stroke | 0 |
| History of smoking | 15 (100%) |
| Packyears | 48.4 ± 29.6 |
| COPD | 6 (40%) |
Data are presented as n (%) or mean plus standard deviation (n = 15).
AAA: abdominal aortic aneurysms; COPD: chronic obstructive pulmonary disease.
Figure 1:
Correlation between aortic diameter (mm) and serum tenascin C levels (pg/ml) in patient cohort of AAA (n = 15).
Figure 2:

Representative three-dimensional reconstructed computed tomography images as well as tenascin C serum levels obtained from 2 abdominal aortic aneurysms patients.
Animal characteristics and aorta diameter in mice
In total, 81 animals were used (WT-SHAM: n = 17, WT-AAA: n = 23, TNC KO-SHAM: n = 18, TNC KO-AAA: n = 23). No deaths due to aortic rupture or dissection were observed. The animals did not show any significant differences in body weight prior to AAA induction (WT-SHAM: 25.2 ± 1.8 g, WT-AAA: 24.8 ± 1.8 g, TNC KO-SHAM: 26.6 ± 3.1 g, TNC KO-AAA: 25.8 ± 2.5 g; n.s.). In WT and TNC KO mice, AAA groups showed a significant increase in aortic diameter ratio compared to sham-operated mice 3 and 10 weeks after AAA induction (3 weeks: WT-SHAM versus WT-AAA: P < 0.001, TNC KO-SHAM versus TNC KO-AAA: P < 0.05; 10 weeks: WT-SHAM versus WT-AAA: P < 0.001, TNC KO-SHAM versus TNC KO-AAA: P < 0.05, Fig. 3). Whereas no significant changes in diameter ratios were found in sham groups (3 weeks: WT-SHAM: 0.96 ± 0.22, TNC KO-SHAM: 0.92 ± 0.08, n.s.; 10 weeks: WT-SHAM: 0.94 ± 0.10, TNC KO-SHAM: 1.05 ± 0.16, n.s.), TNC KO mice with AAA showed a significantly lower diameter ratio compared to the WT group 3 weeks (TNC KO: 1.39 ± 0.25, WT: 1.67 ± 0.22, P < 0.05, Fig. 3A) and 10 weeks (TNC KO: 1.51 ± 0.47, WT: 1.98 ± 0.55, P < 0.05, Fig. 3B) after AAA induction, respectively.
Figure 3:
Aortic diameter ratio between the aortic size at AAA induction and during organ harvesting at 3 weeks (A) and 10 weeks (B) post-induction. Data are shown as mean plus standard deviation. *P < 0.05, for the level of significance in the comparison between WT-AAA and tenascin C KO-AAA (one-way ANOVA with Tukey-HSD post hoc test). AAA: abdominal aortic aneurysms; KO: knock out; WT: wild-type mice.
Tenascin C immunochemistry
TNC expression was markedly increased 3 weeks after AAA induction in WT mice compared to sham-operated mice (WT-SHAM: 0.33 ± 0.52, WT-AAA: 2.25 ± 0.69, P < 0.001, Fig. 4A). In WT mice with AAA TNC was mainly expressed in the tunica media. In addition, sham-operated WT mice and both sham-operated as well as AAA TNC KO mice did not show any specific TNC staining.
Figure 4:
Expression of TNC 3 weeks after AAA induction (A) as well as representative images of TNC immunohistochemistry of the WT-SHAM (B) and the WT-AAA group (C). Data are shown as mean plus standard deviation. ***P < 0.001, for the level of significance in the comparison between WT-SHAM and WT-AAA (unpaired T-test). WT-SHAM: n = 6, WT-AAA: n = 6. Original magnification, 200×. AAA: abdominal aortic aneurysms; TNC: tenascin C; WT: wild-type mice.
Elastin structure
Sham-operated groups showed no signs of elastin degradation. AAA in WT mice had more degraded elastin fibres as well as focal infiltrates of leukocytes compared to TNC KO mice with AAA showing more dilated and less degraded elastin fibres (Fig. 5A–C; WT-AAA: 3.25 ± 0.75, TNC KO-AAA: 2.32 ± 1.15, P < 0.05).
Figure 5:
Scoring of elastin structure in Elastica van Gieson staining 10 weeks after AAA induction (A). Representative images of the WT-AAA group with severe elastin degradation and inflammatory cell infiltrates (B) and the TNC KO-AAA group with mild distention (C). Data are shown as mean plus standard deviation. *P < 0.05, for the level of significance in the comparison between WT-AAA and TNC KO-AAA (unpaired T-test). WT-AAA: n = 10, TNC KO-AAA: n = 14. Original magnification, 200×. AAA: abdominal aortic aneurysms; KO: knock out; TNC: tenascin C; WT: wild-type mice.
The effect of tenascin C on human aortic vascular smooth muscle cells
To further explain the role of TNC in AAA, human aortic VSMC were incubated with TNC or Ang II. Both conditions resulted in a massive up-regulation of matrix metalloproteinase 2 (Fig. 6A; Control: 0.94 ± 0.23, TNC: 2.02 ± 0.64, TNC+TAK242: 1.05 ± 0.23; Ang II: 1.69 ± 0.44; Control versus Ang II: P < 0.05, Control versus TNC: P < 0.01, TNC versus TNC+TAK242: P < 0.001) and COL3 (Fig. 6B; Control: 0.80 ± 0.30, TNC: 1.90 ± 0.64, TNC+TAK242: 0.84 ± 0.21; Ang II: 2.02 ± 0.33; Control versus Ang II: P < 0.001, Control versus TNC: P < 0.01, TNC versus TNC+TAK242: P < 0.01). More interestingly, administration of TNC as well as Ang II further increased the expression of TNC (Fig. 6D; Control: 1.02 ± 0.22, TNC: 1.78 ± 0.59, TNC+TAK242: 0.78 ± 0.20; Ang II: 1.89 ± 0.31; Control versus Ang II: P < 0.01, Control versus TNC: P < 0.05, TNC versus TNC+TAK242: P < 0.001) and angiotensin-converting enzyme 1 (Fig. 6E; Control: 0.77 ± 0.39, TNC: 1.53 ± 0.51, TNC+TAK242: 0.82 ± 0.11; Ang II: 1.66 ± 0.28; Control versus Ang II: P < 0.01, Control versus TNC: P < 0.05, TNC versus TNC+TAK242: P < 0.05) in VSMC. The effect of TNC depended on Toll-like receptor 4 (TLR-4) activation. Similar to that, the up-regulation of matrix metalloproteinase 2 and Col 3 by TNC was markedly declined in presence of the TLR-4 inhibitor TAK242. The expression of Elastin was significantly down-regulated after TNC and Ang II incubation. Hereby, the effect of TNC was not reversible by TLR-4 inhibition (Fig. 6C; Control: 1.24 ± 0.39, TNC: 0.67 ± 0.31, TNC+TAK242: 0.46 ± 0.09; Ang II: 0.86 ± 0.14; Control versus Ang II: P < 0.05, Control versus TNC: P < 0.01, TNC versus TNC+TAK242: n.s.).
Figure 6:
Expression matrix metalloproteinase 2 (A), Col3 (B), Elastin (C), TNC (D) as well as angiotensin-converting enzyme 1 (E) in human aortic vascular smooth muscle cells culture supernatant measured by reverse transcription and quantitative polymerase chain reaction after incubation with TNC. TNC+ TAK242 and Ang II. *P < 0.05, **P < 0.01 and ***P < 0.001, for the level of significance in the comparison between Control and TNC, TNC and TNC+TAK242 (1-way ANOVA with Tukey-HSD post hoc test) as well as Control and Ang II (unpaired T-test). TNC: tenascin C.
DISCUSSION
Selective and sensitive biomarkers for longitudinal monitoring of AAA disease activity are missing. Moreover, despite successful surgical and interventional repair, no causative pharmacological treatment for patients with AAA has been proven in randomized placebo-controlled trials. According to the results of our present study, we observed a consistent trend towards correlation between abdominal aortic diameter and TNC serum levels in patients with AAA. In line with this clinical finding in an experimental model of CaCl2-induced AAA, TNC deficient mice showed a significantly reduced AAA formation and progression as well as markedly reduced elastin disruption compared to WT mice. Mechanistically, TNC like Ang II induces the expression of ECM remodelling associated proteins as well as positive feedback loops in human aortic VSMC. This effect was partially reversed by TLR-4 inhibition.
TNC is a matricellular protein, which is expressed during embryogenesis, cancer and various remodelling processes. Its expression is modulated by cytokines, other matricellular proteins as well as mechanical stress [8]. VSMCs are the main source of TNC in the aorta. TNC expression is associated with the formation of AAA [3]. Furthermore, TNC was mainly expressed in the border zones of the AAA, mostly affected by inflammation and thereby may regulate the progression of AAA [3, 4, 17].
In the present study, we measured the levels of serum TNC in 15 patients with AAA. We could observe a trend towards a correlation between TNC levels and AAA diameter. Importantly, there are no evidence-based studies assessing serum TNC as prognostic marker for AAA. However, in patients with Type A dissection, we and others have demonstrated that TNC levels in plasma as well as in aortic tissue were elevated [5, 18, 19]. Furthermore, higher serum TNC levels were associated with increased in-hospital mortality after acute Type A and Type B dissection, suggesting the maladaptive role of TNC [20, 21]. These findings contradict another study, where elevated serum TNC levels on Day 7 after acute Type B dissection were associated with a lower risk for chronic aortic enlargement [22]. Further studies on larger populations need to elucidate the role of TNC as a marker for AAA progression as well as its time-dependent role in AAA and other aortic diseases.
Next, we wanted to test the hypothesis that TNC is involved in the progression of AAA. We used a model of CaCl2-induced AAA in WT and TNC-KO mice. In line with previous studies, TNC expression in AAA in WT mice was markedly localized in the border area and showed a massive up-regulation [3]. Previous investigations have already indicated that TNC was mostly expressed within mononuclear inflammatory cell infiltrates in human AAA associated with chronic inflammation and linked to neovascularization [23].
In our study, TNC deficient mice showed an attenuated AAA formation 3 and 10 weeks after periaortic CaCl2 application linked to a reduced elastin degradation. Our findings demonstrate contradictory results with the data of Kimura et al. [24]. Kimura et al. reported an increased rate of suprarenal dissections and ruptures in TNC KO mice in a model of CaCl2 induced AAA combined with Ang II infusions. The authors conclude that TNC acted protective on increased haemodynamic stress on the descending thoracic aorta due to CaCl2 induced abdominal aortic stiffening and Ang II infusions. Moreover, no significant differences between AAA diameter in TNC-KO and WT mice were found 6 weeks after CaCl2 induced AAA induction. Of importance, aortic size measurements were conducted ex vivo by histology and not compared to the baseline diameter in each animal [3]. It is important to stress that in the present study, we followed the animals for 3 and 10 weeks after CaCl2 induced AAA [24]. There was an increase in diameter over time and a significant difference between the aortic diameter in TNC KO animals as compared to WT after AAA induction.
In human aortic VSMC similarly to Ang II, incubation with TNC led to up-regulation of matrix metalloproteinase 2 and Col3 as well as to a down-regulation of Elastin. In combination with the increased Elastin degradation observed in WT mice with AAA, TNC could promote adverse aortic remodelling [25]. As a sign of positive feedback loop, Ang II as well as TNC induced TNC and angiotensin-converting enzyme 1 expression. Comparable effects of TNC could be observed in cardiac fibroblasts by our group [16]. These changes were partially reversed by the application of the TLR-4 antagonist TAK242. TNC is a known ligand of integrins as well as TLR-4 and subsequently interferes with matricellular proteins such as fibronectin facilitating cell migration [4, 26]. Additionally, it induces the NFκB signalling pathway via TLR-4 activation in various cell types including macrophages and fibroblasts, and consequently accelerates proinflammatory cytokine expression which also play a central role in AAA pathophysiology [2, 27, 28]. Based on these experimental results and the trend in our clinical cohort, we assume that TNC might play a maladaptive rather than beneficial role in the formation and progression of AAA.
Limitations
Certain limitations need to be acknowledged. First, our patient cohort was small including only AAA patients, men only and therefore underpowered to detect a significant correlation between AAA diameter and TNC serum levels. This takes into account that men show an up to 3- to 6-fold increased prevalence of AAA [1, 29]. Moreover, only male animals were included. Second, CaCl2 induced AAA show aortic wall thickening and do not develop intraluminal thromboses compared to other models like the elastase model. However, the CaCl2 model does not require aortic clamping as well as an aortotomy and is therefore less invasive as well as less susceptible for induction flaws. Additionally, using the CaCl2 model, mice do not develop ruptures or aortic dissections. No further in vivo aortic size measurements (e.g. ultrasound) have been performed in addition to the intraoperative size evaluation [14, 30]. Third, we were not able to perform reverse transcription and quantitative polymerase chain reactions or other methods including MMP zymography on murine aortic samples because of the limited tissue. This limitation will be addressed in future studies.
CONCLUSION
Higher serum TNC in patients with AAA might be associated with increased disease activity and aortic wall instability. Due to the preclinical observation with a trend of correlation between TNC expression and progression of AAA diameter, we suggest to prepare a larger clinical study to clarify the role of TNC as prognostic marker in AAA.
SUPPLEMENTARY MATERIAL
Supplementary material is available at ICVTS online.
Supplementary Material
ACKNOWLEDGEMENTS
The authors thank the staff of the Center for Biomedical Research, Medical University of Vienna for animal care and Milat Inci as a valuable laboratory technician.
Funding
This work was supported by the Ludwig Boltzmann Institute for Cardiovascular Research, REM 2017/20, Vienna, Austria.
Conflict of interest: none declared.
Glossary
- ABBREVIATIONS
- AAA
Abdominal aortic aneurysms
- Ang II
Angiotensin II
- CaCl2
Calcium chloride
- KO
Knock out mice
- TLR-4
Toll-like receptor 4
- TNC
Tenascin C
- VSMC
Vascular smooth muscle cells
- WT
Wild-type mice
Author contributions
Felix Nagel: Conceptualization; Data curation; Investigation; Methodology; Project administration; Visualization; Writing—original draft. Anne-Kristin Schaefer: Data curation; Investigation; Project administration. Inês Fonseca Gonçalves: Data curation; Investigation. Eylem Acar: Data curation; Investigation. Andre Oszwald: Data curation; Investigation. Philipp Kaiser: Data curation; Investigation. Renate Kain: Data curation; Investigation. Karola Trescher: Conceptualization. Wolf Hans Eilenberg: Data curation. Christine Brostjan: Data curation; Writing—review & editing. David Santer: Conceptualization; Investigation; Methodology; Project administration; Writing—review & editing. Attila Kiss: Conceptualization; Investigation; Methodology; Project administration; Writing—review & editing. Bruno Karl Podesser: Conceptualization; Funding acquisition; Investigation; Methodology; Writing—review & editing.
Reviewer information
Interactive CardioVascular and Thoracic Surgery thanks George J. Arnaoutakis, Luca Bertoglio, Mario Giovanni Gerardo D'Oria and the other anonymous reviewer(s) for their contribution to the peer review process of this article.
REFERENCES
- 1. Wanhainen A, Verzini F, Van Herzeele I, Allaire E, Bown M, Cohnert T. et al. Editor's choice—European Society for Vascular Surgery (ESVS) 2019 clinical practice guidelines on the management of abdominal aorto-iliac artery aneurysms. Eur J Vasc Endovasc Surg 2019;57:8–93. [DOI] [PubMed] [Google Scholar]
- 2. Golledge J. Abdominal aortic aneurysm: update on pathogenesis and medical treatments. Nat Rev Cardiol 2019;16:225–42. [DOI] [PubMed] [Google Scholar]
- 3. Kimura T, Yoshimura K, Aoki H, Imanaka-Yoshida K, Yoshida T, Ikeda Y. et al. Tenascin-C is expressed in abdominal aortic aneurysm tissue with an active degradation process. Pathol Int 2011;61:559–64. [DOI] [PubMed] [Google Scholar]
- 4. Imanaka-Yoshida K, Matsumoto K.. Multiple roles of tenascins in homeostasis and pathophysiology of aorta. Ann Vasc Dis 2018;11:169–80. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Trescher K, Thometich B, Demyanets S, Kassal H, Sedivy R, Bittner R. et al. Type A dissection and chronic dilatation: tenascin-C as a key factor in destabilization of the aortic wall. Interact CardioVasc Thorac Surg 2013;17:365–70. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Podesser BK, Kreibich M, Dzilic E, Santer D, Förster L, Trojanek S. et al. Tenascin-C promotes chronic pressure overload-induced cardiac dysfunction, hypertrophy and myocardial fibrosis. Journal of Hypertension 2018;36:847–56. https://doi.org/ 10.1097/HJH.0000000000001628. [DOI] [PubMed] [Google Scholar]
- 7. Santer D, Nagel F, Gonçalves IF, Kaun C, Wojta J, Fagyas M. et al. Tenascin‐C aggravates ventricular dilatation and angiotensin‐converting enzyme activity after myocardial infarction in mice. ESC Heart Failure 2020;7:2113–22. https://doi.org/ 10.1002/ehf2.12794. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Midwood KS, Hussenet T, Langlois B, Orend G.. Advances in tenascin-C biology. Cell Mol Life Sci 2011;68:3175–99. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Yuan W, Zhang W, Yang X, Zhou L, Hanghua Z, Xu K.. Clinical significance and prognosis of serum tenascin-C in patients with sepsis. BMC Anesthesiol 2018;18:170. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Piccinini AM, Midwood KS.. Endogenous control of immunity against infection: tenascin-C regulates TLR4-mediated inflammation via microRNA-155. Cell Rep 2012;2:914–26. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Koyama Y, Kusubata M, Yoshiki A, Hiraiwa N, Ohashi T, Irie S. et al. Effect of tenascin-C deficiency on chemically induced dermatitis in the mouse. J Invest Dermatol 1998;111:930–5. [DOI] [PubMed] [Google Scholar]
- 12. Nakao N, Hiraiwa N, Yoshiki A, Ike F, Kusakabe M.. Tenascin-C promotes healing of Habu-snake venom-induced glomerulonephritis: studies in knockout congenic mice and in culture. Am J Pathol 1998;152:1237–45. [PMC free article] [PubMed] [Google Scholar]
- 13. Matsuda A, Yoshiki A, Tagawa Y, Matsuda H, Kusakabe M.. Corneal wound healing in tenascin knockout mouse. Invest Ophthalmol Vis Sci 1999;40:1071–80. [PubMed] [Google Scholar]
- 14. Chiou AC, Chiu B, Pearce WH.. Murine aortic aneurysm produced by periarterial application of calcium chloride. J Surg Res 2001;99:371–6. [DOI] [PubMed] [Google Scholar]
- 15. Krishna SM, Seto SW, Jose RJ, Biros E, Moran CS, Wang Y. et al. A peptide antagonist of thrombospondin-1 promotes abdominal aortic aneurysm progression in the angiotensin II-infused apolipoprotein-E-deficient mouse. Arterioscler Thromb Vasc Biol 2015;35:389–98. [DOI] [PubMed] [Google Scholar]
- 16. Perera-Gonzalez M, Kiss A, Kaiser P, Holzweber M, Nagel F, Watzinger S. et al. The role of tenascin C in cardiac reverse remodeling following banding-debanding of the ascending aorta. Int J Mol Sci 2021;22:2023. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Didangelos A, Yin X, Mandal K, Saje A, Smith A, Xu Q. et al. Extracellular matrix composition and remodeling in human abdominal aortic aneurysms: a proteomics approach. Mol Cell Proteomics 2011;10:M111.008128. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Matsumoto K, Satoh K, Maniwa T, Tanaka T, Okunishi H, Oda T.. Proteomic comparison between abdominal and thoracic aortic aneurysms. Int J Mol Med 2014;33:1035–47. [DOI] [PubMed] [Google Scholar]
- 19. Majumdar R, Miller DV, Ballman KV, Unnikrishnan G, McKellar SH, Sarkar G. et al. Elevated expressions of osteopontin and tenascin C in ascending aortic aneurysms are associated with trileaflet aortic valves as compared with bicuspid aortic valves. Cardiovasc Pathol 2007;16:144–50. [DOI] [PubMed] [Google Scholar]
- 20. Nozato T, Sato A, Hirose S, Hikita H, Takahashi A, Endo H. et al. Preliminary study of serum tenascin-C levels as a diagnostic or prognostic biomarker of type B acute aortic dissection. Int J Cardiol 2013;168:4267–9. [DOI] [PubMed] [Google Scholar]
- 21. Guo T, Zhou X, Zhu A, Peng W, Zhong Y, Chai X.. The role of serum tenascin-C in predicting in-hospital death in acute aortic dissection. Int Heart J 2019;60:919–23. [DOI] [PubMed] [Google Scholar]
- 22. Nozato T, Sato A, Hikita H, Takahashi A, Imanaka-Yoshida K, Yoshida T. et al. Impact of serum tenascin-C on the aortic healing process during the chronic stage of type B acute aortic dissection. Int J Cardiol 2015;191:97–9. [DOI] [PubMed] [Google Scholar]
- 23. Satta J, Soini Y, Pöllänen R, Pääkkö P, Juvonen T.. Tenascin expression is associated with a chronic inflammatory process in abdominal aortic aneurysms. J Vasc Surg 1997;26:670–5. [DOI] [PubMed] [Google Scholar]
- 24. Kimura T, Shiraishi K, Furusho A, Ito S, Hirakata S, Nishida N. et al. Tenascin C protects aorta from acute dissection in mice. Sci Rep 2014;4:4051. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25. Rabkin SW. The role matrix metalloproteinases in the production of aortic aneurysm. Prog Mol Biol Transl Sci 2017;147:239–65. [DOI] [PubMed] [Google Scholar]
- 26. Imanaka-Yoshida K, Hiroe M, Yoshida T.. Interaction between cell and extracellular matrix in heart disease: multiple roles of tenascin-C in tissue remodeling. Histol Histopathol 2004;19:517–25. [DOI] [PubMed] [Google Scholar]
- 27. Midwood K, Sacre S, Piccinini AM, Inglis J, Trebaul A, Chan E. et al. Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat Med 2009;15:774–80. [DOI] [PubMed] [Google Scholar]
- 28. Midwood KS, Chiquet M, Tucker RP, Orend G.. Tenascin-C at a glance. J Cell Sci 2016;129:4321–7. [DOI] [PubMed] [Google Scholar]
- 29. Ulug P, Powell JT, Sweeting MJ, Bown MJ, Thompson SG; SWAN Collaborative Group. Meta-analysis of the current prevalence of screen-detected abdominal aortic aneurysm in women. Br J Surg 2016;103:1097–104. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30. Busch A, Bleichert S, Ibrahim N, Wortmann M, Eckstein H-H, Brostjan C. et al. Translating mouse models of abdominal aortic aneurysm to the translational needs of vascular surgery. JVS Vasc Sci 2021;2:219–34. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.






